EMA

The European Medicines Agency (EMA) explains that "there is currently no evidence of the need for a fourth dose in the general population". It warns: 'Short-term recalls may reduce antibodies'

The European Medicines Agency Ema explains that administering the vaccine six to eight months after the second dose promotes an increase in antibodies. However, the decision remains a national competence

EMA has recommended granting an extension of indication to Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA), a rare…

EMA has started evaluating an application to extend the use of Kineret (anakinra) to include treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia who are at risk of developing severe respiratory failure…